Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 21;99(3):477–486. doi: 10.1007/s00277-020-03907-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Impact of CD318 expression on clinical outcome. a Overall survival (OS) in AML patients according to CD318^lo and CD318^hi expression in Kaplan-Meier analysis. b Overall survival in patients without intense therapy according to CD318^lo and CD318^hi expression in Kaplan-Meier analysis. Mean OS was reached in CD318^lo (dotted line) and CD318^hi (continuous line) after 14 or 194.5 days, respectively, and differed significantly (log-rank test). c Overall survival in patients receiving hypomethylating agents according to CD318^lo and CD318^hi expression in Kaplan-Meier analysis. d Overall survival in patients receiving anthracyclin-based induction therapy (ABIT) according to CD318^lo and CD318^hi expression in Kaplan-Meier analysis. Mean OS was only reached in CD318^hi after 572 days (dotted line; log-rank test). e Progression-free survival (PFS) according to CD318^lo and CD318^hi expression in Kaplan-Meier analysis. In CD318^hi, the mean PFS was 513 days (dotted line; log-rank test) and could not be reached in CD318^lo (continuous line)